Search company, investor...

Emphasys Medical

Founded Year



Series E | Alive

Total Raised


Last Raised

$18.14M | 17 yrs ago

About Emphasys Medical

Emphasys Medical has developed an innovative device called the Emphasys Endobronchial Valve* (EBV). The EBV is implanted in the diseased portions of the lung and utilizes a one-way valve to prevent air from entering the diseased lung segments during inhalation yet allows trapped air to vent during exhalation. This design is intended to allow inhaled air to be redirected to the healthier, functional parts of the lung. The Emphasys procedure is a minimally invasive treatment option in which the device is placed in selectively targeted areas of the affected lung determined by the extent of the emphysema damage.

Headquarters Location

700 Chesapeake Drive

Redwood City, California, 94063,

United States


Missing: Emphasys Medical's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Emphasys Medical's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Latest Emphasys Medical News

Endobronchial Valves Market Revenue to Record Stellar Growth Rate During 2018 – 2028

Jan 31, 2020

Endobronchial valves were developed  primarily by the start-up medical device company Emphasys Medical (now Pulmonx – Redwood City, California) as a minimally invasive alternative to lung volume reduction surgery for emphysema. In lung volume reduction surgery, a surgeon cuts into a patient’s chest and cuts out one or more diseased portion(s) of a lung. Endobronchial valves were designed to replicate the effects of that procedure without requiring incisions, by simply allowing the most diseased portions of the lung to collapse. Emphasys was purchased by Pulmonx in 2009 Chronic obstructive pulmonary disease (COPD) is a widespread, progressive lung disease for which pulmonologists in the US have had few new treatment options available outside the standard pharmacological therapies, lung rehabilitation and high-risk lung volume reduction surgery. Now emerging technologies, in particular, endobronchial valves, which aim to shrink hyperinflated lungs in severe emphysema patients, could soon become the first minimally invasive treatment option available in the US. Enquiry More About This Report: The major factor expected to drive the growth of the endobronchial valves market is growing awareness regarding procedure for bronchoscopic lung volume reduction in various lung-related diseases. The increasing prevalence of tobacco smoking worldwide is consequently expected to contribute to the growth of the endobronchial valves market. The chronic obstructive pulmonary disease (COPD) is one of the major lung disorders. With the growing geriatric population, who are more commonly susceptible to lung disease, the demand for endobronchial valve is expected to increase at a linear speed. Endobronchial Valves Market: Segmentation Request  Report For Toc: The global endobronchial valves market can be segmented on the basis of product type, end user, and geography. Based on product type, the global endobronchial valves market is segmented as: Duckbill-shaped Endobronchial Valves, Umbrella-shaped Endobronchial Valves Based on the end user, the global endobronchial valves market is segmented as: Hospitals,Clinical Research Center, Ambulatory Surgery Center, Others Regional analysis includes: North America (U.S., Canada), Latin America (Mexico, Brazil, Argentina, Chile, Peru, rest of Latin America), Europe (Germany, Italy, U.K, Spain, France, Nordic countries, BENELUX, Eastern Europe, rest of Europe), CIS & Russia, Asia Pacific Excluding Japan (Greater China, India, South Korea, ASEAN Countries, Rest of APEJ), Japan, Middle East and Africa (GCC, S. Africa, Turkey, Iran, Israel, Rest of MEA) Key players operating in the market include Pulmonx Corporation (Zephyr), SpirationInc, etc. Full View of Report Description:

Emphasys Medical Frequently Asked Questions (FAQ)

  • When was Emphasys Medical founded?

    Emphasys Medical was founded in 2000.

  • Where is Emphasys Medical's headquarters?

    Emphasys Medical's headquarters is located at 700 Chesapeake Drive, Redwood City.

  • What is Emphasys Medical's latest funding round?

    Emphasys Medical's latest funding round is Series E.

  • How much did Emphasys Medical raise?

    Emphasys Medical raised a total of $58.3M.

  • Who are the investors of Emphasys Medical?

    Investors of Emphasys Medical include Morgan Stanley, Morgenthaler Ventures, ABS Ventures, Advanced Technology Ventures, OrbiMed Advisors and 10 more.

  • Who are Emphasys Medical's competitors?

    Competitors of Emphasys Medical include MicroTransponder, Broncus Medical, Avedro, ReShape Medical, Uptake Medical and 12 more.

Compare Emphasys Medical to Competitors

Endologix Logo

Endologix is a developer and manufacturer of minimally invasive treatments for vascular diseases. Endologix is focusing on the development and marketing of its patented technology for the treatment of Abdominal Aortic Aneurysms (AAA). An aneurysm is a weakening of the wall of the aorta, the largest artery of the body. Aortic aneurysm disease is a cause of death in the United States and it is estimated that 1.7 million persons over 55 years of age have an AAA. Each year, physicians diagnose approximately 200,000 people in the United States with AAA. Endologix is currently marketing its Powerlink Delivery System a, one-piece endoluminal stent graft (ELG) used in treating AAA that has significant advantages when compared with marketed stent alternatives. Powerlink has been commercially available in Europe since 1999. FDA approval for the Powerlink AAA stent graft was received on October 29, 2004. The Powerlink superior design is covered by 17 U.S. patents with 361 allowed claims; the technology is designed to overcome shortcomings of first-generation ELGs. The device is for sale in the United States and selected international markets. Endologix is a publicly-held company trading on NASDAQ: ELGX. The company's corporate office is located in Irvine, California.

Varix Medical

Varix Medical Corporation, located in Sunnyvale, Calif., is a medical device company focused on developing products for the minimally invasive treatment of chronic venous insufficiency, commonly referred to as "varicose veins." For patients with advanced stages of varicose veins, laser- and RF-based (radiofrequency) treatments have been developed, but each device has deficiencies making them less-than-optimal solutions. Varix Medical's platform technology will enable physicians to efficiently and effectively treat more types of diseased veins than is currently possible when using either laser or RF devices. Additional treatable vessels include tortuous sub-truncal vessels and other visible smaller varicose veins. The Varix platform employs a vapor-based endovenous ablation system that will consist of a disposable catheter, a catheter introducer or delivery system, and a reusable vapor generator. RCT and Coronis Medical Ventures LLC., formed Varix in August 2007 and acquired the technology under license from Tsunami MedTech LLC. Coronis and RCT have been the primary in investors in Varix.

Axial Biotech

Axial Biotech, founded in 2002 by a group of spine surgeons and geneticists, is focused on the use of genetics and the development of minimally invasive fusionless devices to advance the diagnosis and treatment of diseases and deformities of the human spine. Axial is a company to pursue DNA-based pre-symptomatic and prognostic tests for common spinal conditions which will augment current clinical and surgical practices. In its initial genetic product development initiative, Axial has made progress towards the discovery of a location in the human genome that is associated with adolescent idiopathic scoliosis. In addition, Axial's founders have developed five motion preserving, fusionless surgical devices (including such device currently being implanted in humans) that have the promise of expanding the current treatable scoliosis patient population by a factor of ten. Axial intends to use its genetic intellectual property in the development of bio-mechanical devices, and to apply its gene discovery/product development methodology to other spinal diseases. Axial ( is located in Salt Lake City, Utah.


DuoCure offers intraluminal minimally invasive implantable device for treatment of obesity.

MicroTransponder Logo

MicroTransponder is a global medical device company committed to developing research-based neuroscience solutions. The company focuses on restoring independence and dignity for people suffering from neurological conditions that impair sensory and motor function. MicroTransponder's FDA-approved Vivistim® Paired VNS™ System is a clinically-proven medical technology that generates more improvement in upper limb function than rehabilitation alone for stroke survivors after 6 weeks of in-clinic therapy. MicroTransponder was founded in 2007 and is based in Austin, Texas.


Researcher and developer of a minimally invasive, encapsulated cellular transplant device for the treatment of diabetes. The company sold its assets to Novocell.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.